Last €35.84 EUR
Change Today +0.075 / 0.21%
Volume 3.1K
NOVA On Other Exchanges
New York
As of 1:02 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

novo-nordisk a/s-spons adr (NOVA) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/1/14 - €38.67
52 Week Low
11/1/13 - €24.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVO-NORDISK A/S-SPONS ADR (NOVA)

Related News

No related news articles were found.

novo-nordisk a/s-spons adr (NOVA) Details

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation. The company sells its products primarily in North America, China, Japan, Algeria, Argentina, Australia, Brazil, India, Turkey, and European countries through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

40,226 Employees
Last Reported Date: 08/7/14
Founded in 1925

novo-nordisk a/s-spons adr (NOVA) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: kr15.2M
President, Chief Operating Officer and Member...
Total Annual Compensation: kr9.0M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer, Executive Vice Preside...
Total Annual Compensation: kr8.1M
Chief of Staff, Executive Vice President and ...
Total Annual Compensation: kr7.0M
Compensation as of Fiscal Year 2013.

novo-nordisk a/s-spons adr (NOVA) Key Developments

Novo Nordisk Seeks Listing Of NNIT

Novo Nordisk A/S (CPSE:NOVO B) is mulling a listing of NNIT A/S on the Copenhagen stock exchange, daily Berlingske reported. Novo Nordisk has hired Morgan Stanley and Danske Bank as advisors.

Novo Nordisk Establishes New Obesity Research Unit in Seattle; Kevin Grove Appoints as Head of the Novo Nordisk Obesity Research Unit

Novo Nordisk announced that the company will establish a new obesity research unit in Seattle, Washington, in the US. The new unit is a result of Novo Nordisk's increasing focus on treatment of obesity. Its main task will be to identify novel approaches and targets for obesity treatments while increasing the scientific understanding of existing obesity targets. Dr Kevin Grove has accepted the position as head of the Novo Nordisk Obesity Research Unit in Seattle. Grove is a renowned expert in endocrinology specialising in obesity and health-related quality of life, and joins Novo Nordisk from a position as senior scientist at the Oregon Health & Science University, and founding division chief, Division of Diabetes, Obesity & Metabolism.

Novo Nordisk and Egyvac to Open Joint Insulin Plant in Egypt

Novo Nordisk has signed a partnership deal with the Egyptian Company for Production of Vaccines (EGYVAC). The two companies plan to collaborate on the construction of a human insulin factory in Egypt, with Novo Nordisk transferring technology related to the manufacture of insulin. In addition to the partnership, Novo Nordisk plans to establish 26 specialist diabetes treatment centres and provide 60,000 patients with free insulin pens.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVA:GR €35.84 EUR +0.075

NOVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $56.90 USD +0.61
Amgen Inc $143.64 USD -0.45
Bristol-Myers Squibb Co $51.84 USD -0.11
Eli Lilly & Co $64.68 USD 0.00
Reckitt Benckiser Group PLC 5,015 GBp +5.00
View Industry Companies

Industry Analysis


Industry Average

Valuation NOVA Industry Range
Price/Earnings 25.3x
Price/Sales 7.7x
Price/Book 17.7x
Price/Cash Flow 20.1x
TEV/Sales 6.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at